GSK
817 hedge funds and large institutions have $11.1B invested in GSK in 2020 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 246 increasing their positions, 344 reducing their positions, and 109 closing their positions.
15% more capital inflows, than outflows
Capital inflows: $1.52B | Capital outflows: $1.32B
7% more call options, than puts
Call options by funds: $105M | Put options by funds: $98.5M
0.17% more ownership
Funds ownership: 11.81% → 11.99% (+0.17%)
1% less funds holding
Funds holding: 825 → 817 (-8)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
28% less repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 344
47% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 109
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$659M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$121M |
| 3 |
Camber Capital Management
Boston,
Massachusetts
|
+$112M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$109M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$76.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$149M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$103M |
| 3 |
Rockefeller Capital Management
New York
|
-$98.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$84.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$83.3M |
GSK Hedge Fund Activity: Q4 2020 in Review
817 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2020, worth a combined $11.1B — down 0.73% from $11.2B a quarter earlier.
Sellers outnumbered buyers: 109 funds closed out of GSK and 58 opened new positions — a net loss of 51 holders — while 344 trimmed existing stakes and 246 added.
The largest buyer was Dodge & Cox, adding an estimated $659M. The largest seller was Renaissance Technologies, cutting an estimated $149M.
- 817 institutional investors held GSK (GSK) as of Q4 2020, down from 825 in Q3 2020.
- Funds reported $11.1B of GSK stock for Q4 2020, down 0.73% quarter-over-quarter.
- 58 funds opened new GSK positions in Q4 2020 and 109 closed out, a net change of -51 holders.
- The largest GSK buyer in Q4 2020 was Dodge & Cox, an estimated $659M added.
- The largest GSK seller in Q4 2020 was Renaissance Technologies, an estimated $149M sold.
Based on aggregated 13F filings for Q4 2020.